Barclays Maintains an 'Underweight' on Chemed (CHE); Updating Estimates After 4Q10 Earnings
Tweet Send to a Friend
Barclays maintains an 'Underweight' on Chemed (NYSE: CHE), PT increased from $65 to $69.
Barclay analyst says, "...On this point ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclay analyst says, "...On this point ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
